Calcium folinate pentahydrate
Neoplastic Syndrome
University of California, San FranciscoSmall moleculePhase 2/3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Neoplastic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM University of California, San Francisco | Phase 2/3 | BB |
Irinotecan University of California, San Francisco | Phase 2/3 | BB |
Thalidomide Memorial Sloan Kettering Cancer Center | Phase 2 | B |
Eloxatin University of California, San Francisco | Phase 2/3 | B |
Docetaxel Eastern Cooperative Oncology Group | Phase 2 | B |
(+)-VINCRISTINE University of California, San Francisco | Phase 2/3 | B |
Octreotide Pamoate Eastern Cooperative Oncology Group | Phase 2 | B |
Motesanib Eastern Cooperative Oncology Group | Phase 2 | CC |
Same molecule, other indications
Calcium folinate pentahydrate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →